Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Summary

This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned after a period of improvement. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2013-04-30

Primary completion

2029-12-31

Completion

2029-12-31

Outcome

Missed primary endpoint

paper Although the initial primary outcome objective of the study was not met PMID 33754642 ↗

Publications

• Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021 Jun 24;137(25):3473-3483. doi: 10.1182/blood.2020009688.

Drugs

Indications